Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

17.9%

82 terminated/withdrawn out of 457 trials

Success Rate

79.4%

-7.1% vs industry average

Late-Stage Pipeline

25%

114 trials in Phase 3/4

Results Transparency

73%

230 of 317 completed trials have results

Key Signals

15 recruiting230 with results71 terminated11 withdrawn

Enrollment Performance

Analytics

Phase 1

129(36.3%)

Phase 2

105(29.6%)

Phase 3

66(18.6%)

Phase 4

48(13.5%)

N/A

6(1.7%)

Early Phase 1

1(0.3%)

355Total

Phase 1(129)

Phase 2(105)

Phase 3(66)

Phase 4(48)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (457)

Showing 20 of 457 trials

NCT04457778Phase 1Completed

First in Human Study of M6223

Role: collaborator

NCT05081180Phase 1Active Not Recruiting

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Role: collaborator

NCT06589713Phase 1Completed

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Role: collaborator

NCT05004350Phase 2Completed

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Role: collaborator

NCT06710132Phase 1Recruiting

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Role: collaborator

NCT07332481Phase 3Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Role: collaborator

NCT07355218Phase 3Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Role: collaborator

NCT07166601Phase 1Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Role: collaborator

NCT05782361Phase 1Active Not Recruiting

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

Role: collaborator

NCT07549412Phase 3Not Yet Recruiting

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Role: collaborator

NCT05464030Phase 1Recruiting

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Role: collaborator

NCT06806046Phase 1Active Not Recruiting

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

Role: collaborator

NCT05198349Phase 1Terminated

First in Human Study of M1069 in Advanced Solid Tumors

Role: collaborator

NCT07499362Phase 2Recruiting

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Role: collaborator

NCT07110038Phase 2Recruiting

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Role: collaborator

NCT05910827Phase 1Recruiting

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Role: collaborator

NCT05376891Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

Role: collaborator

NCT01118676Phase 1Completed

Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Role: collaborator

NCT02864992Phase 2Active Not Recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)